- Home
- VELO vs TCRX Comparison
VELO vs TCRX Comparison
Compare VELO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VELO
- TCRX
- Stock Information
- Founded
- VELO 2014
- TCRX 2018
- Country
- VELO United States
- TCRX United States
- Employees
- VELO N/A
- TCRX N/A
- Industry
- VELO Industrial Machinery/Components
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- VELO Technology
- TCRX Health Care
- Exchange
- VELO Nasdaq
- TCRX Nasdaq
- Market Cap
- VELO 85.8M
- TCRX 91.7M
- IPO Year
- VELO N/A
- TCRX 2021
- Fundamental
- Price
- VELO $3.60
- TCRX $1.91
- Analyst Decision
- VELO
- TCRX Strong Buy
- Analyst Count
- VELO 0
- TCRX 5
- Target Price
- VELO N/A
- TCRX $9.40
- AVG Volume (30 Days)
- VELO 1.4M
- TCRX 208.8K
- Earning Date
- VELO 11-07-2025
- TCRX 08-12-2025
- Dividend Yield
- VELO N/A
- TCRX N/A
- EPS Growth
- VELO N/A
- TCRX N/A
- EPS
- VELO N/A
- TCRX N/A
- Revenue
- VELO $43,765,000.00
- TCRX $6,961,000.00
- Revenue This Year
- VELO N/A
- TCRX $255.18
- Revenue Next Year
- VELO N/A
- TCRX N/A
- P/E Ratio
- VELO N/A
- TCRX N/A
- Revenue Growth
- VELO N/A
- TCRX N/A
- 52 Week Low
- VELO $1.43
- TCRX $1.02
- 52 Week High
- VELO $29.25
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- VELO N/A
- TCRX 59.09
- Support Level
- VELO N/A
- TCRX $1.73
- Resistance Level
- VELO N/A
- TCRX $1.95
- Average True Range (ATR)
- VELO 0.00
- TCRX 0.12
- MACD
- VELO 0.00
- TCRX 0.01
- Stochastic Oscillator
- VELO 0.00
- TCRX 84.85
About VELO Velo3D Inc. Common stock
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.